Quel est le prix pour D. Western Therapeutics Institute, Inc. (4576)

Le prix pour D. Western Therapeutics Institute, Inc. (4576) est $0.56109583

Quelle est la capitalisation boursière pour D. Western Therapeutics Institute, Inc. (4576)

La capitalisation boursière pour D. Western Therapeutics Institute, Inc. (4576) est $32.25M

Revenus de D. Western Therapeutics Institute, Inc. (4576)

D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.

Année	Revenus	Changez
Pas assez de données pour les dates fournies.

Année

Revenus

Changez

Pas assez de données pour les dates fournies.

Entreprise	Revenus	Différence de revenus	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Moderna, Inc. MRNA.US	$2.23B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Entreprise

Revenus

Différence de revenus

Pays